Towards Europe 2050: the role of institutions, EU research, and citizens for climate justice. The urban challenge in Amsterdam, Bilbao, Freiburg, and Lisbon.

The climate crisis is the greatest challenge humanity has ever faced, and in 2023 the average global temperature reached new records, prompting the UN Secretary General to declare that 'the era of global warming is over, and the era of global boiling has arrived'. In this context, urban areas play a key role, and can be considered a bottleneck of the climate crisis. The European Commission is investing billions of euros in research and innovation projects in urban areas, while the European Green Deal strategy has the ambition of making Europe the first carbon-neutral continent on the planet by 2050. However, studies and research show that the causes of the climate crisis are rooted in an economic system that produces profound inequalities, and the very solutions to address the consequences of global warming risk deepening them. In this context, the role of cities is not only to decarbonise their urban fabric, but to build solutions to the social challenge posed by the climate crisis, promoting paradigm shifts capable of producing trajectories towards so-called 'climate justice'. This research analyses, through a holistic view, European policies in these fields, and delves into the actions and projects of four European cities - Amsterdam, Bilbao, Freiburg, and Lisbon - through a qualitative approach aimed at identifying strengths and contradictions of strategies to tackle the climate crisis. Delving into the collective dynamics and social impacts of the actions promoted, the research proposes a comprehensive view of the role that urban areas can play not only in decarbonising society, but in promoting a paradigm shift capable of addressing the economic causes and social consequences of the climate crisis.

Study of the urinary biomarkers of synthetic cannabinoid receptor agonists (SCRAs) for the forensic unequivocal proof of consumption: medico-legal implications for drug abuse prevention

Introduction. Synthetic cannabinoid receptor agonists (SCRAs) represent the widest group of New Psychoactive Substances (NPS) and, around 2021-2022, new compounds emerged on the market. The aims of the present research were to identify suitable urinary markers of Cumyl-CB-MEGACLONE, Cumyl-NB-MEGACLONE, Cumyl-NB-MINACA, 5F-EDMB-PICA, EDMB-PINACA and ADB-HEXINACA, to present data on their prevalence and to adapt the methodology from the University of Freiburg to the University of Bologna. Materials and methods. Human phase-I metabolites detected in 46 authentic urine samples were confirmed in vitro with pooled human liver microsomes (pHLM) assays, analyzed by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-qToF-MS). Prevalence data were obtained from urines collected for abstinence control programs. The method to study SCRAs metabolism in use at the University of Freiburg was adapted to the local facilities, tested in vitro with 5F-EDMB-PICA and applied to the study of ADB-HEXINACA metabolism. Results. Metabolites built by mono, di- and tri-hydroxylation were recommended as specific urinary biomarkers to monitor the consumption of SCRAs bearing a cumyl moiety. Monohydroxylated and defluorinated metabolites were suitable proof of 5F-EDMB-PICA consumption. Products of monohydroxylation and amide or ester hydrolysis, coupled to monohydroxylation or ketone formation, were recognized as specific markers for EDMB-PINACA and ADB-HEXINACA. The LC-qToF-MS method was successfully adapted to the University of Bologna, as tested with 5F-EDMB-PICA in vitro metabolites. Prevalence data showed that 5F-EDMB-PINACA and EDMB-PINACA were more prevalent than ADB-HEXINACA, but for a limited period. Conclusion. Due to undetectability of parent compounds in urines and to shared metabolites among structurally related compounds, the identification of specific urinary biomarkers as unequivocal proofs of SCRAs consumption remains challenging for forensic laboratories. Urinary biomarkers are necessary to monitor SCRAs abuse and prevalence data could help in establishing tailored strategies to prevent their spreading, highlighting the role for legal medicine as a service to public health.